PMID- 37750641
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20231019
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 17
DP  - 2023 Sep
TI  - Efficacy of hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery 
      for advanced or recurrent ovarian cancer: a systematic evaluation and 
      meta-analysis.
PG  - 8135-8143
LID - 33573 [pii]
LID - 10.26355/eurrev_202309_33573 [doi]
AB  - OBJECTIVE: This meta-analysis was performed to investigate the safety and 
      efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with 
      cytoreductive surgery (CRS) in the treatment of advanced or recurrent ovarian 
      cancer. MATERIALS AND METHODS: An electronic search of databases, including 
      PubMed, Embase, Cochrane, Medline, and Web of Science, was performed to collect 
      controlled studies on HIPEC combined with CRS administered for advanced ovarian 
      cancer. Meta-analysis was conducted based on the outcome indicators extracted 
      from the included studies, including disease-free survival (DFS), overall 
      survival (OS), and adverse events (AEs). RESULTS: Twelve pieces of literature 
      were included, involving 1,622 participants, with 694 participants in the control 
      group and 928 in the study group. In terms of DFS, the pooled hazard ratio (HR) 
      was 0.70 (95% CI: 0.58, 0.84), with an HR of 0.77 (95% CI: 0.64, 0.93) in the 
      treatment-naive subgroup and an HR of 0.54 (95% CI: 0.40, 0.74) in the secondary 
      cytoreduction subgroup. In terms of OS, the pooled HR was 0.63 (95% CI: 0.52, 
      0.77), with an HR of 0.67 (95% CI: 0.54, 0.83) in the treatment-naive subgroup 
      and an HR of 0.47 (95% CI: 0.29, 0.77) in the secondary cytoreduction subgroup. 
      With regard to AEs, the pooled odds ratio (OR) was 0.79 (95% CI: 0.68, 0.92). 
      CONCLUSIONS: The benefits of CRS plus HIPEC for the management of advanced 
      ovarian cancer are significant but also associated with an increased risk of 
      adverse events. Thus, clinical use of this co-administration requires caution.
FAU - Li, H
AU  - Li H
AD  - Gynecology Department, Longyan First Affiliated Hospital of Fujian Medical 
      University, Longyan, China. liaolanjin007@163.com.
FAU - Liao, L-J
AU  - Liao LJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - Female
MH  - Humans
MH  - *Cytoreduction Surgical Procedures
MH  - Hyperthermic Intraperitoneal Chemotherapy
MH  - Carcinoma, Ovarian Epithelial
MH  - Databases, Factual
MH  - *Ovarian Neoplasms/surgery
EDAT- 2023/09/26 13:43
MHDA- 2023/09/27 06:43
CRDT- 2023/09/26 08:33
PHST- 2023/09/27 06:43 [medline]
PHST- 2023/09/26 13:43 [pubmed]
PHST- 2023/09/26 08:33 [entrez]
AID - 33573 [pii]
AID - 10.26355/eurrev_202309_33573 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Sep;27(17):8135-8143. doi: 
      10.26355/eurrev_202309_33573.